Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.25
AZN's Cash to Debt is ranked lower than
83% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. AZN: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
AZN' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 2.52 Max: N/A
Current: 0.25
Equity to Asset 0.23
AZN's Equity to Asset is ranked lower than
92% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. AZN: 0.23 )
Ranked among companies with meaningful Equity to Asset only.
AZN' s Equity to Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.44 Max: 0.59
Current: 0.23
0.23
0.59
Interest Coverage 7.90
AZN's Interest Coverage is ranked lower than
68% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. AZN: 7.90 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 5.58  Med: 8.64 Max: 15.02
Current: 7.9
5.58
15.02
F-Score: 7
Z-Score: 1.65
M-Score: -2.56
WACC vs ROIC
6.92%
15.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 17.04
AZN's Operating margin (%) is ranked higher than
77% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. AZN: 17.04 )
Ranked among companies with meaningful Operating margin (%) only.
AZN' s Operating margin (%) Range Over the Past 10 Years
Min: 8.19  Med: 29.04 Max: 38.09
Current: 17.04
8.19
38.09
Net-margin (%) 11.78
AZN's Net-margin (%) is ranked higher than
71% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. AZN: 11.78 )
Ranked among companies with meaningful Net-margin (%) only.
AZN' s Net-margin (%) Range Over the Past 10 Years
Min: 4.73  Med: 20.91 Max: 29.72
Current: 11.78
4.73
29.72
ROE (%) 17.02
AZN's ROE (%) is ranked higher than
79% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. AZN: 17.02 )
Ranked among companies with meaningful ROE (%) only.
AZN' s ROE (%) Range Over the Past 10 Years
Min: 5.89  Med: 37.06 Max: 45.52
Current: 17.02
5.89
45.52
ROA (%) 5.06
AZN's ROA (%) is ranked higher than
58% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. AZN: 5.06 )
Ranked among companies with meaningful ROA (%) only.
AZN' s ROA (%) Range Over the Past 10 Years
Min: 2.2  Med: 14.19 Max: 20.88
Current: 5.06
2.2
20.88
ROC (Joel Greenblatt) (%) 58.30
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. AZN: 58.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AZN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 28.15  Med: 124.05 Max: 199.48
Current: 58.3
28.15
199.48
Revenue Growth (3Y)(%) -1.60
AZN's Revenue Growth (3Y)(%) is ranked lower than
71% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. AZN: -1.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AZN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.9  Med: 1.50 Max: 19.9
Current: -1.6
-42.9
19.9
EBITDA Growth (3Y)(%) -14.90
AZN's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. AZN: -14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AZN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.9  Med: -0.70 Max: 24.7
Current: -14.9
-38.9
24.7
EPS Growth (3Y)(%) -21.50
AZN's EPS Growth (3Y)(%) is ranked lower than
82% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. AZN: -21.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AZN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.8  Med: 12.90 Max: 32.1
Current: -21.5
-48.8
32.1
» AZN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

AZN Guru Trades in Q2 2015

NWQ Managers 153,255 sh (+486.45%)
Murray Stahl 26,000 sh (+300.00%)
Jim Simons 3,934,600 sh (+149.47%)
Pioneer Investments 759,059 sh (+100.15%)
John Hussman 42,000 sh (+61.54%)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
Steven Cohen 50,200 sh (unchged)
Francis Chou 13,000 sh (unchged)
Steven Cohen Sold Out
David Dreman Sold Out
Mario Gabelli 4,200 sh (-28.81%)
» More
Q3 2015

AZN Guru Trades in Q3 2015

Ken Fisher 27,947 sh (New)
PRIMECAP Management 183,900 sh (New)
NWQ Managers 490,535 sh (+60.04%)
Pioneer Investments 1,522,676 sh (+0.30%)
Francis Chou 26,000 sh (unchged)
Manning & Napier Advisors, Inc 455,740 sh (unchged)
Mario Gabelli Sold Out
Jim Simons 5,452,900 sh (-30.71%)
Murray Stahl 28,000 sh (-46.15%)
John Hussman 2,000 sh (-97.62%)
» More
Q4 2015

AZN Guru Trades in Q4 2015

Dodge & Cox 11,777,132 sh (New)
Ken Fisher 221,606 sh (+692.95%)
PRIMECAP Management 988,900 sh (+437.74%)
Pioneer Investments 2,201,690 sh (+44.59%)
NWQ Managers 516,215 sh (+5.24%)
Manning & Napier Advisors, Inc 459,840 sh (+0.90%)
John Hussman 2,000 sh (unchged)
Murray Stahl 28,000 sh (unchged)
Jim Simons 4,959,700 sh (-9.04%)
Francis Chou 13,000 sh (-50.00%)
» More
Q1 2016

AZN Guru Trades in Q1 2016

Jeremy Grantham 408,300 sh (New)
PRIMECAP Management 13,084,275 sh (+1223.11%)
Dodge & Cox 26,049,650 sh (+121.19%)
Jim Simons 5,682,800 sh (+14.58%)
Manning & Napier Advisors, Inc 487,770 sh (+6.07%)
Ken Fisher 233,409 sh (+5.33%)
Murray Stahl 28,302 sh (+1.08%)
John Hussman 2,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
NWQ Managers 506,785 sh (-1.83%)
Pioneer Investments 446,513 sh (-79.72%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:BAYZF, NYSE:LLY, NYSE:ABBV, OTCPK:GLAXF, NYSE:SNY, OTCPK:ALPMY, NYSE:BMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:OPHLY, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHF, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:GWPRF, OTCPK:MAYNF, NAS:HCM, AMEX:TXMD, OTCPK:HAWPF » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, OXAZN.Switzerland, AZN.UK, AZNCF.USA,
AstraZeneca PLC is a biopharmaceutical company. It is engaged in the discovery and development of new products, which are then manufactured, marketed and sold.

AstraZeneca PLC was incorporated in England and Wales on June 17, 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company is engaged in the discovery and development of new products, which are then manufactured, marketed and sold. It is engaged in healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.

Ratios

vs
industry
vs
history
P/E(ttm) 30.35
AZN's P/E(ttm) is ranked lower than
52% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.13 vs. AZN: 30.35 )
Ranked among companies with meaningful P/E(ttm) only.
AZN' s P/E(ttm) Range Over the Past 10 Years
Min: 6.03  Med: 12.15 Max: 99.72
Current: 30.35
6.03
99.72
Forward P/E 14.66
AZN's Forward P/E is ranked higher than
59% of the 81 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.13 vs. AZN: 14.66 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.35
AZN's PE(NRI) is ranked lower than
52% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.09 vs. AZN: 30.35 )
Ranked among companies with meaningful PE(NRI) only.
AZN' s PE(NRI) Range Over the Past 10 Years
Min: 6.03  Med: 12.15 Max: 99.72
Current: 30.35
6.03
99.72
Price/Owner Earnings (ttm) 23.56
AZN's Price/Owner Earnings (ttm) is ranked higher than
69% of the 271 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.32 vs. AZN: 23.56 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AZN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.38  Med: 11.61 Max: 28.08
Current: 23.56
5.38
28.08
P/B 5.64
AZN's P/B is ranked lower than
76% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.98 vs. AZN: 5.64 )
Ranked among companies with meaningful P/B only.
AZN' s P/B Range Over the Past 10 Years
Min: 2.3  Med: 3.77 Max: 6.97
Current: 5.64
2.3
6.97
P/S 3.54
AZN's P/S is ranked lower than
56% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.77 vs. AZN: 3.54 )
Ranked among companies with meaningful P/S only.
AZN' s P/S Range Over the Past 10 Years
Min: 1.61  Med: 2.40 Max: 3.92
Current: 3.54
1.61
3.92
PFCF 34.02
AZN's PFCF is ranked lower than
62% of the 201 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.87 vs. AZN: 34.02 )
Ranked among companies with meaningful PFCF only.
AZN' s PFCF Range Over the Past 10 Years
Min: 6.18  Med: 13.49 Max: 179.65
Current: 34.02
6.18
179.65
POCF 19.13
AZN's POCF is ranked lower than
54% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.82 vs. AZN: 19.13 )
Ranked among companies with meaningful POCF only.
AZN' s POCF Range Over the Past 10 Years
Min: 5.35  Med: 8.64 Max: 26.98
Current: 19.13
5.35
26.98
EV-to-EBIT 27.64
AZN's EV-to-EBIT is ranked lower than
64% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.83 vs. AZN: 27.64 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.3  Med: 8.50 Max: 61
Current: 27.64
4.3
61
EV-to-EBITDA 16.22
AZN's EV-to-EBITDA is ranked higher than
54% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.31 vs. AZN: 16.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.6  Med: 6.80 Max: 20.5
Current: 16.22
3.6
20.5
Shiller P/E 17.51
AZN's Shiller P/E is ranked higher than
87% of the 151 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 50.92 vs. AZN: 17.51 )
Ranked among companies with meaningful Shiller P/E only.
AZN' s Shiller P/E Range Over the Past 10 Years
Min: 10  Med: 13.56 Max: 21.11
Current: 17.51
10
21.11
Current Ratio 0.80
AZN's Current Ratio is ranked lower than
94% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. AZN: 0.80 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.49 Max: 2.03
Current: 0.8
0.64
2.03
Quick Ratio 0.65
AZN's Quick Ratio is ranked lower than
91% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. AZN: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.26 Max: 2.03
Current: 0.65
0.54
2.03
Days Inventory 181.10
AZN's Days Inventory is ranked lower than
78% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. AZN: 181.10 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 122.07 Max: 157.83
Current: 181.1
88.45
157.83
Days Sales Outstanding 98.16
AZN's Days Sales Outstanding is ranked lower than
67% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.90 vs. AZN: 98.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.12  Med: 68.49 Max: 95.12
Current: 98.16
59.12
95.12
Days Payable 307.34
AZN's Days Payable is ranked higher than
95% of the 581 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.75 vs. AZN: 307.34 )
Ranked among companies with meaningful Days Payable only.
AZN' s Days Payable Range Over the Past 10 Years
Min: 147.39  Med: 213.74 Max: 543.62
Current: 307.34
147.39
543.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.50
AZN's Dividend Yield is ranked higher than
92% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.28 vs. AZN: 4.50 )
Ranked among companies with meaningful Dividend Yield only.
AZN' s Dividend Yield Range Over the Past 10 Years
Min: 1.95  Med: 4.58 Max: 7.64
Current: 4.5
1.95
7.64
Dividend Payout 1.22
AZN's Dividend Payout is ranked lower than
91% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. AZN: 1.22 )
Ranked among companies with meaningful Dividend Payout only.
AZN' s Dividend Payout Range Over the Past 10 Years
Min: 0.23  Med: 0.93 Max: 4.87
Current: 1.22
0.23
4.87
Dividend Growth (3y) -1.80
AZN's Dividend Growth (3y) is ranked lower than
66% of the 287 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. AZN: -1.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
AZN' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -4.5  Med: 11.10 Max: 28.3
Current: -1.8
-4.5
28.3
Forward Dividend Yield 6.10
AZN's Forward Dividend Yield is ranked higher than
96% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. AZN: 6.10 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.99
AZN's Yield on cost (5-Year) is ranked higher than
87% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. AZN: 4.99 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AZN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.16  Med: 5.08 Max: 8.48
Current: 4.99
2.16
8.48
3-Year Average Share Buyback Ratio -0.50
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 420 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.20 vs. AZN: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.3  Med: 1.80 Max: 4.9
Current: -0.5
-23.3
4.9

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.60
AZN's Price/Projected FCF is ranked higher than
72% of the 308 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.65 vs. AZN: 1.60 )
Ranked among companies with meaningful Price/Projected FCF only.
AZN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.49  Med: 1.29 Max: 5.98
Current: 1.6
0.49
5.98
Price/Median PS Value 1.48
AZN's Price/Median PS Value is ranked lower than
67% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. AZN: 1.48 )
Ranked among companies with meaningful Price/Median PS Value only.
AZN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.16 Max: 2.48
Current: 1.48
0.39
2.48
Earnings Yield (Greenblatt) (%) 3.60
AZN's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. AZN: 3.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AZN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 11.70 Max: 23.1
Current: 3.6
1.6
23.1
Forward Rate of Return (Yacktman) (%) -15.95
AZN's Forward Rate of Return (Yacktman) (%) is ranked lower than
87% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.55 vs. AZN: -15.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AZN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -17.3  Med: 18.50 Max: 27.5
Current: -15.95
-17.3
27.5

More Statistics

Revenue (TTM) (Mil) $24,766
EPS (TTM) $ 1.15
Beta0.54
Short Percentage of Float1.00%
52-Week Range $26.97 - 34.88
Shares Outstanding (Mil)2,530.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 23,789 23,842 26,557
EPS ($) 2.17 2.20 2.52
EPS w/o NRI ($) 2.17 2.20 2.52
EPS Growth Rate
(3Y to 5Y Estimate)
1.42%
Dividends Per Share ($) 1.42 1.46 1.62
» More Articles for NYSE:AZN

Headlines

Articles On GuruFocus.com
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 
Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
Francis Chou Doubles Stake in AstraZeneca Aug 11 2015 
Last Month Insiders Bought Over $300 Million Of This Biotech Jun 26 2015 
Guru Stocks at 52-Week Lows: XOM, WMT, CVX, AZN, COP Jun 21 2015 
Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 

More From Other Websites
Corporate raiders seek Brexit bargains in Britain Jul 24 2016
3 post-Brexit picks I’d buy now Jul 22 2016
Relypsa Getting Acquired By Swiss Partner Seeking U.S. Entry Jul 21 2016
Here’s what Neil Woodford has been buying and selling since the Brexit vote Jul 21 2016
Your inhaler's watching you: drugmakers race for smart devices Jul 20 2016
Your inhaler's watching you: drugmakers race for smart devices Jul 20 2016
Your inhaler's watching you: drugmakers race for smart devices Jul 20 2016
Indian Firms Get Approval for Generics of AstraZeneca Drug Jul 20 2016
Judge refuses to block generic versions of AstraZeneca's Crestor Jul 19 2016
Judge refuses to block generic versions of AstraZeneca's Crestor Jul 19 2016
Judge refuses to block generic versions of AstraZeneca's Crestor Jul 19 2016
AstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint Jul 19 2016
AstraZeneca Fails to Keep Generic Crestor Rivals Off Market Jul 19 2016
FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque... Jul 19 2016
FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque... Jul 19 2016
U.S. FDA panel backs Valeant psoriasis drug with risk program Jul 19 2016
Will GlaxoSmithKline plc and AstraZeneca plc continue to be Brexit winners? Jul 19 2016
SoftBank to buy UK chip designer ARM in $32 bln cash deal Jul 18 2016
AstraZeneca lung cancer drug meets late-stage trial endpoint Jul 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)